Announcements Trials

Browse Landscape

Phase

Phase 4 6 Phase 2 3 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1

Interventions

Cisplatin 725 Carboplatin 607 Paclitaxel 578 Cyclophosphamide 516 Radiotherapy 511 Docetaxel 475 Fluorouracil 453 Gemcitabine 437 Doxorubicin 383 Capecitabine 361 Dexamethasone 327 Oxaliplatin 288 pembrolizumab 283 Leucovorin 282 Bevacizumab 275 Etoposide 271 Vincristine 270 Rituximab 246 Prednisone 222 Pemetrexed 217 Cytarabine 205 Drug Therapy 194 Trastuzumab 175 Irinotecan 172 Methotrexate 171 Lenalidomide 137 Nivolumab 135 Filgrastim 135 Epirubicin 129 Tamoxifen 127

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Meropenem × Clear all

NCT05392634 2022-05-31

MACS

N.N. Petrov National Medical Research Center of Oncology

Phase 3 Unknown

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡